Evolus, Inc. (EOLS) SEC Filings & Earnings Calls

GAAP operating loss of $4.5M, though improving; still not GAAP profitable.

“GAAP Operating Loss of $4.5 Million” · word for word

Dependence on FDA approval for Evolysse Sculpt and Profhilo commercialization timeline (2030).

“Continued advancing Evolysse Sculpt through the FDA review process ... Profhilo with Anticipated U.S. Commercialization in 2030” · word for word

Tariff exposure on imported products

“Changes in trade policies, including increased or proposed tariffs in the United States or retaliatory tariffs in response to such have caused an increase in our cost of goods related to our products.” · word for word

Consumer discretionary spending sensitivity

“Recent macroeconomic events, including inflationary pressures and threatened and imposed tariffs have negatively impacted consumer sentiment, resulted in decreased procedural volume for cash-pay medical aesthetics treatments, especially in the United States, and have impacted our customer’s liquidity and purchasing behaviors.” · word for word

Dependence on single suppliers for key products

“We depend solely upon Daewoong for the manufacturing of Jeuveau ® , on Symatese to manufacture Evolysse ® and will rely on IBSA to manufacture Profhilo ® .” · word for word

Regulatory approval risk; commercialization expected in 2028

“Milestone payments contingent on regulatory approvals; expected commercialization in 2028”

Regulatory and commercial risk: Profhilo requires FDA approval; minimum purchase commitments post-launch.

“The Company will be responsible ... for U.S. development, clinical and regulatory activities intended to support FDA approval”

Termination of at-the-market sales agreement may indicate reduced need for equity financing, but could also signal limited future capital access.

“Terminated the Sales Agreement that had provided for up to $50.0 million of shares; no shares had been sold.”

Tariff exposure on imported products

“For example, we source our Evolysse ® products, which are classified as medical devices, from France, and our Jeuveau ® product, which is classified as a pharmaceutical product, from South Korea, and since 2025 they have been subject to implemented and further threatened tariffs.” · word for word

Consumer demand sensitivity to macro conditions

“Recent macroeconomic events, including inflationary pressures and threatened and imposed tariffs have negatively impacted consumer sentiment, resulted in decreased procedural volume for cash-pay medical aesthetics treatments, especially in the United States, and have impacted our customer’s liquidity and purchasing behaviors.” · word for word

Continued losses and cash burn

“We recorded net loss of $10.7 million for the three months ended March 31, 2026, and we recorded a net losses of $51.6 million and $50.4 million for the years ended December 31, 2025 and 2024, respectively. We had an accumulated deficit of $671.7 million as of March 31, 2026.” · word for word

Royalty obligations limit pricing flexibility

“Under the agreement, we remain obligated to pay to Medytox a mid-single digit royalty percentage on net sales of Jeuveau ® in the United States and all territories we have licensed outside the United States until September 16, 2032.” · word for word

Dependence on third-party manufacturers and suppliers

“We are reliant on Symatese to achieve and maintain regulatory approval for the Evolysse ® product line in the United States.” · word for word

Consumer demand slowdown in aesthetics market

“After the second quarter of 2025, it became apparent to the compensation committee that its initial assumptions as to growth in the U.S. aesthetics market during 2025 were too aggressive and that the corporate financial performance goals it initially established for the 2025 bonus program were unlikely to be attained based on actual market conditions during ” · word for word

Executive turnover

“Mrs. Beaver and Mrs. Yamagishi-Dressler departed the Company in June and August 2025, respectively.” · word for word

Regulatory non-compliance risk

“Our failure to comply with all applicable regulatory requirements... may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions.” · word for word

Post-marketing cost risk

“Any regulatory approvals... may also be subject to limitations... or contain requirements for potentially costly post-marketing testing.”

Healthcare fraud liability

“We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse... any violations by us of such laws could result in fines or other penalties.” · word for word

Derivative litigation

“Derivative lawsuits have been filed against us and certain of our officers and directors, which could result in substantial costs and could divert management attention.” · word for word

Credit facility secured by substantially all assets, increasing creditor control risk.

“All obligations under the Loan Agreement are secured by substantially all of the assets of the Company.”

High interest rate (SOFR + 4.25%) increases financing costs.

“Borrowings bear interest at adjusted term SOFR (floor 2.0%) plus 4.25% margin.”

Market growth assumptions may be conservative; recalibrated long-term targets reflect cautious outlook.

“We have recalibrated our long-term financial targets to reflect growing market share against a more conservative market growth outlook” · word for word

Tariff exposure on imported products

“We source our Evolysse™ products from France, and these products were subject to a 10% tariff in the second quarter of 2025 and as a result of a recent U.S. trade deal with the European Union these products will be subject to a 15% tariff.” · word for word

Cash burn and liquidity risk

“Cash used in operating activities was $55.1 million in the nine months ended September 30, 2025, compared to cash used in operating activities of $22.8 million in the nine months ended September 30, 2024.” · word for word

Dependence on single suppliers for key products

“We rely on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau®. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau®.”

Gross margin pressure from tariffs and product mix

“Our gross profit margin was 66.5% and 68.9% for the three months ended September 30, 2025 and 2024, respectively.” · word for word

Restructuring costs of $1.4M incurred for cost structure optimization; indicates ongoing expense management.

“we incurred $1.4 million in restructuring related expenses primarily consisting of one-time severance benefits” · word for word